RAVEL-TECHNOLOGIES
23.8.2022 19:28:16 CEST | Business Wire | Press release
Ravel Technologies S.A.S. (“Ravel'' or “Company”) proudly unveils several major patent-pending breakthroughs in Fully Homomorphic Encryption (FHE). Now 4 orders of magnitude faster than state-of-the-art, Ravel’s algorithmic discoveries are designed to make FHE finally scalable. The team is now building a sophisticated suite of fully encrypted technologies including the first fully encrypted SQL database equipped to query billions of encrypted data points, as well as advanced machine learning algorithms.
“Now that we have successfully overcome FHE’s biggest challenges, we will begin to put its uniquely powerful, protective capabilities to work,” explains Ravel CEO Mehdi Sabeg. “We have identified exciting opportunities in financial markets and privacy-preserving personalised advertising. We plan to address a full spectrum of vertically-diverse use cases, such as health data management, supply chain, financial services, and public services utilising our data sharing and analytics platform.”
Ravel includes a team of outstanding senior researchers in mathematics and is advised by Fields Medal Recipient Cedric Villani.
“Given the impressive, major algorithmic breakthroughs achieved by Ravel’s team, Ravel Fully Homomorphic Encryption (RHE) is orders of magnitude faster than state-of-the-art FHE schemes,” notes Villani. “With the continual increase of personal and industrial data being processed globally, privacy, and confidentiality protection are of paramount importance. Ravel’s breakthroughs bring an efficient and scalable answer to critical data privacy and security challenges.”
Ravel’s ability to process encrypted data with low latency and high throughput provides unparalleled de-identification capabilities that can also facilitate targeted advertisements with zero-knowledge of the consumer. Brands worldwide have long sought after exactly this solution, one that doesn’t infringe on the privacy of their users.
In the same fashion, Ravel can operate fully encrypted financial exchanges and remove certain market biases induced by plaintext data that can be exploited in the bidding process, for example. In this sector, confidentiality protection becomes increasingly important for large financial institutions starting to rely on transparent blockchain infrastructure.
“As we experienced during our Proof of Concept, Ravel has demonstrated that its technology can enable secure and efficient processing for high volumes of encrypted data,” BNP Paribas Group Chief Information Officer and Executive Committee Member Bernard Gavgani confirms. “They are well on their way to solving data sharing and analytics challenges in banking and finance for brands worldwide. We look forward to pursuing our collaboration.”
As Ravel strengthens its technological edge, the team is focused on scaling up its commercial growth, with a concentration on building out its presence across the US and European markets.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220823005745/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
